Tag: DurAVR transcatheter heart valve
$38.5M investment to expand Anteris’ manufacturing capacity, global clinical program
Anteris Technologies Global Corp has announced a binding agreement for a private placement valued at approximately AUD 38.5 million (USD 25.2 million) to support the advancement of its PARADIGM clinical trial and accelerate global commercialisation efforts.
Anteris granted utility patent for heart valve replacement technology
Australian biotechnology company Anteris Technologies announced that the United States Patent and Trademark Office has issued a utility patent for its novel DurAVR transcatheter heart valve (THV).
Featured Article
Modular switchgear built for faster, verified panel builds
As switchboard builders face tighter programmes and increasing scrutiny around compliance, the way enclosure, busbar and separation concepts work together has a direct impact on build time and verification effort.
